Medical/Pharmaceuticals

Gastrointestinal Biotech Company Renexxion Ireland Announces $100M Investment Commitment

ROSCREA, Ireland, April 12, 2022 /PRNewswire/ -- Renexxion Ireland Ltd., a private biopharmaceutical company committed to delivering innovative drugs to patients with high unmet need in gastrointestinal ("GI") disorders, announced today that it has entered into a share subscription agreement with...

2022-04-12 20:00 925

Esaote S.p.A. turns 40 and is confirmed as a leading player in the world market for diagnostic imaging with ultrasound systems, magnetic resonance imaging and information technology for healthcare

GENOA, Italy, April 12, 2022 /PRNewswire/ -- Esaote S.p.A., a leading biomedical company in the diagnostic imaging sector - in the fields of ultrasound, magnetic resonance and Information Technology for health - celebrates forty years of activity.  

2022-04-12 19:00 1111

New Clinical Advisory Board to support PromarkerD global rollout

* Proteomics International establishes world class Clinical Advisory Board promarkerd.com/clinical-advisory-board * Comprises highly-respected physicians specialising in diabetes and kidney disease care fromthe United States, Europe and Austra...

2022-04-12 16:04 850

CMG901 for the treatment of gastric cancer and gastroesophageal junction adenocarcinoma was granted the Orphan-drug Designation by the Food and Drug Administration of the United States

CHENGDU, China, April 12, 2022 /PRNewswire/ -- Keymed Biosciences (2162.HK) announced that its new drug candidate CMG901 (the "Claudin 18.2 antibody drug conjugates") for the treatment of gastric cancer and gastroesophageal junction adenocarcinoma has been granted the Orphan-drug Designation by t...

2022-04-12 15:45 516

/DISREGARD RELEASE: HanAll Biopharma and Daewoong Pharmaceutical/

We are advised by HanAll Biopharma and Daewoong Pharmaceutical that journalists and other readers should disregard the news release, "Daewoong Pharmaceutical and HanAll Biopharma Invest in Turn Biotechnologies to Expand Growth Initiative", issued11-Apr-2022 over PR Newswire. ...

2022-04-12 15:34 1356

Abbott Senior Medical Director joins Nutromics as inaugural Chief Medical Officer

MELBOURNE, Australia, April 12, 2022 /PRNewswire/ -- Australian and US MedTech start-up Nutromics (Nutromics or the Company), a global leader in DNA-based biosensors, today announced that DrAgim Beshiri, most recently Senior Medical Director at Abbott Laboratories, has joined the organisation as ...

2022-04-12 09:28 682

VenusP-Valve(TM) obtains CE marking under MDR and debuts in Europe as China's first valve product

HANGZHOU, China, April 12, 2022 /PRNewswire/ -- On April 8th, 2022, VenusP-Valve TM, Venus Medtech's in-house developed innovative transcatheter pulmonic valve replacement (TPVR) system, received CE marking under the Medical Devices Regulation (MDR) to be marketed inEurope. Designed to treat patie...

2022-04-12 09:20 644

Strong Growth in Digital Health Powers MediHeroes, A Cross Border B2B Medical Platform

SINGAPORE, April 12, 2022 /PRNewswire/ --  MediHeroes will launch a "Verify Before Buy" platform created especially for suppliers, buyers and service providers in the MedTech industry onApril 15, 2022. A transformative industry platform, MediHeroes helps buyers and sellers save months to years ...

2022-04-12 09:00 842

ProstACT Update: TARGET Study Ethics Approval

MELBOURNE, Australia, April 12, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces its ProstACT TARGET Phase II clinical trial of the Company's prostate cancer antibody therapy candidate TLX591 (177Lu-DOTA-rosopatamab), in patients experiencing a fir...

2022-04-12 07:47 854

The NDA of Henlius Novel Anti-PD-1 mAb Serplulimab for the First-Line Treatment of Small Cell Lung Cancer Accepted by NMPA

SHANGHAI, April 11, 2022 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the New Drug Application (NDA) of HANSIZHUANG (serplulimab), a novel anti-PD-1 monoclonal antibody (mAb) independently developed by the company, in combination with chemotherapy for the first-line tr...

2022-04-11 22:07 1409

PharmAbcine Presents Updated Preclinical Data of Its Anti-VISTA Antibody Candidate at AACR 2022

DAEJEON, South Korea, April 11, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), aclinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today that the Company presented an updated preclinical data PMC-309, the Company's anti-VISTA ...

2022-04-11 20:00 584

Global pharma organizations back Turn Biotechnologies to advance its cell rejuvenation program

Daewoong Pharmaceutical, HanAll Biopharma join Astellas Venture Management and other VCs in oversubscribed funding round to accelerate Turn Bio's preclinical advances in multiple therapeutic areas MOUNTAIN VIEW, Calif., April 11, 2022 /PRNewswire/ -- Turn Biotechnologies, a cell rejuvenation com...

2022-04-11 19:00 1135

APRINOIA Therapeutics received FDA clearance to initiate APNmAb005 Phase 1 clinical trial

BOSTON, April 11, 2022 /PRNewswire/ -- APRINOIA Therapeutics announces today that the U.S. Food and Drug Administration (FDA) has granted a may proceed authorization for its novel therapeutic anti-tau monoclonal antibody, APNmAb005, allowing the company to test and evaluate its safety in healthy ...

2022-04-11 18:00 1197

InventisBio Reported Promising Phase I Study Results of a Novel KRAS G12C Inhibitor D-1553 in Cancer Patients

SHANGHAI, April 11, 2022 /PRNewswire/ -- InventisBio Co., Ltd., a clinical-stage biotech company based inShanghai, China has published the clinical data of their oral KRAS G12C inhibitor D-1553, for the first time in cancer patients. These data are presented in two e-posters at the annual meetin...

2022-04-11 17:37 471

Singapore-based women's healthcare company marks its first Financial Times ranking

Making its debut on the fourth annual Financial Times ranking of 500 of Asia-Pacific's high-growth companies, INEX Innovate - the pioneering healthcare technology company targeting women's health - is one of only 20 healthcare companies listed in the prestigious line up. SINGAPORE, April 11, 202...

2022-04-11 17:21 804

Successful Passing Of The EU Qualified Person Audit Of The Group's Manufacturing Facility For ReCOV In Taizhou

TAIZHOU, China, April 11, 2022 /PRNewswire/ -- The board of directors of Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group",Stock code:2179.HK) is pleased to announce that, on April 9, 2022, the Company has received the European Union (EU) Qualified Pe...

2022-04-11 16:05 1423

CUHK researchers discover distinct gut microbial signatures for prediction, diagnosis and treatment of long COVID

HONG KONG, April 11, 2022 /PRNewswire/ -- Clinical researchers from The Chinese University of Hong Kong's (CUHK) Faculty of Medicine (CU Medicine) have identified for the first time distinct gut microbiome profiles associated with post-acute COVID-19 syndrome, more commonly known as "long COVID"....

2022-04-11 12:35 1434

Honeywell Teams with AstraZeneca to Develop Next-Generation Respiratory Inhalers That Use Near-Zero Global Warming Potential Propellant

* Next-generation inhaler will use Honeywell's Solstice® Air to reduce greenhouse gas emissions of propellant by up to 99.9 percent vs current inhaler propellant * Further demonstrates Honeywell's commitment to greenhouse gas reduction and support of customers' sustainability goals through in...

2022-04-11 09:00 994

Antengene Announces Publication of Five Posters at the 2022 American Association for Cancer Research (AACR) Annual Meeting

The company will present the preclinical data of five novel drug candidates at AACR 2022 (onApril 8-13). Focus on ATG-037, ATG-018, ATG-022, ATG-012 and ATG-008. SHANGHAI and HONG KONG, April 11, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovativ...

2022-04-11 08:30 1791

Innovent Release Phase 1 Results of IBI322 (anti-PD-L1/CD47 bispecific antibody) in patients with advanced solid tumors at AACR Annual Meeting 2022

SAN FRANCISCO and SUZHOU, China, April 11, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major dise...

2022-04-11 08:14 1461
1 ... 259260261262263264265 ... 577